<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368543">
  <stage>Registered</stage>
  <submitdate>17/05/2015</submitdate>
  <approvaldate>3/06/2015</approvaldate>
  <actrnumber>ACTRN12615000572561</actrnumber>
  <trial_identification>
    <studytitle>Pilot Study of prototype Intranasal Stent &amp; Positive Expiratory Airway Pressure device to treat Moderate Obstructive Sleep Apnoea</studytitle>
    <scientifictitle>Pilot Study of prototype Intranasal Stent &amp; Positive Expiratory Airway Pressure device to treat Moderate Obstructive Sleep Apnoea</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive Sleep Apnoea</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A phase 1, proof of concept pilot series will evaluate the use of Rhinomed's prototype of an intranasal stent and positive expiratory pressure device (RHI-003 NBV001) for moderate obstructive sleep apnoea. This stenting device contains a one way valve that facilitates inspiration unimpeded and delivers an expiratory resistance that creates expiratory positive pressure to the pharynx. 20 subjects are fitted and trained to self insert the device by the researchers. Polysomnography using the device on night 1 will compare sleep apneoa severity to baseline. Two weeks of nightly usage in their own home will be monitored with self reported compliance log and repeat partner assisted snoring analogue scale questionnaire. Subjects will be assigned a device for night 1 to 3 with a non-therapeutic expiratory effect with 2.5mm valve diameter, nights 3 to 6 with 2mm valve diameter and then nights 7-14 with therapeutic expiratory effect with a 1.5mm valve diameter. This will assist with acclimation.</interventions>
    <comparator>This is a pilot case series without control arm.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the effect of an intranasal expiratory pressure device on moderate obstructive sleep apnoea measured by in laboratory polysomnography</outcome>
      <timepoint>Device response is measured by polysomnography on first night of use. Pilot data measuring self reports of nightly usage will be collected for 14 consecutive nights</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability of an intranasal expiratory pressure device used nightly for 14 trial nights in the domestic environment. This will be determined by a subjective report using 5 point visual analogue scale of comfort and self report of hours of usage per night.</outcome>
      <timepoint>After 14 days of home usage during sleep</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Partner assisted self report of subjective snoring severity measured by an analogue scale</outcome>
      <timepoint>Data will be collected daily for 14 trial days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Moderate obstructive sleep apnoea (apnoea hypopnoea index &gt;15 events per hour and &lt;30 events per hour). 

- Witness in the domestic environment to report on snoring severity.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Unable to fit intranasal stent device comfortably
- Unable to provide informed consent
- Major cardiorespiratory comorbidity
- Current treatment for obstructive sleep apnoea</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Patients with a new diagnosis of moderate obstructive sleep apnoea presenting from respiratory and sleep clinics from Monash Health Melbourne may be notified of the trial. 

A study coordinator will provide information as to the purpose, design and requirements of the study. All consenting subjects will be enrolled into the intervention arm.</concealment>
    <sequence>not applicable</sequence>
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Analysis will be performed using student t test for parametric data.

20 subjects will be enrolled aiming for 20% reduction in severity of obstructive sleep apnoea and 90% power.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>8/06/2015</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Monash Medical Centre - Clayton campus - Clayton</hospital>
    <postcode>3168 - Clayton</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Monash Lung and Sleep</primarysponsorname>
    <primarysponsoraddress>Monash Health 246 Clayton Rd Clayton Victoria 3168</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Rhinomed Limited</fundingname>
      <fundingaddress>1/1233 High Street Armadale 3143 Victoria</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Rhinomed LTD</sponsorname>
      <sponsoraddress>1/1233 High Street Armadale 3143 Victoria</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a phase 1 proof of concept trial measuring the effect of a novel intranasal stent and tolerability of an expiratory positive pressure device on subjects with moderate obstructive sleep apnoea.
Hypothesis: The combination fo dilation of the nasal cavity with an intranasal stent combined with a valve that increases pressure to the upper airway on expiration will favorably effect moderate sleep apnoea and snoring.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>MonashHealth Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 2, I Block Monash Medical Centre
246 Clayton Rd Clayton Victoria 3168</ethicaddress>
      <ethicapprovaldate>22/04/2015</ethicapprovaldate>
      <hrec>15040A</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Darren Mansfield</name>
      <address>Monash Lung and Sleep
Monash Health
246 Clayton Rd 
Clayton 3168
Victoria</address>
      <phone>613 9594 6666</phone>
      <fax>61395946415</fax>
      <email>darren.mansfield@monashhealth.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Darren Mansfield</name>
      <address>Monash Lung and Sleep
Monash Health
246 Clayton Rd 
Clayton
Victoria 3168</address>
      <phone>61395946666</phone>
      <fax>61395946415</fax>
      <email>darren.mansfield@monashhealth.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Darren Mansfield</name>
      <address>Monash Lung and Sleep
Monash Health
246 Clayton Rd 
Clayton
Victoria 3168</address>
      <phone>61395946666</phone>
      <fax>61395946415</fax>
      <email>darren.mansfield@monashhealth.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Darren Mansfield</name>
      <address>Monash Lung and Sleep
Monash Health
246 Clayton Rd 
Clayton</address>
      <phone>61395946666</phone>
      <fax>61395946415</fax>
      <email>darren.mansfield@monashhealth.org</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>